© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights are reserved.
The EMA has initiated a review of dexamethasone as a remedy for adults with COVID-19 who require respiratory assistance and have been hospitalized.
The European Medicines Agency (EMA) announced in a press release of 24 July 2020 that a review of dexamethasone had begun as a remedy for adults with COVID-19 who require respiratory assistance and have been admitted to the hospital.
Specifically, the regulatory firm is reviewing knowledge of the ARM of the RECOVERY study, which evaluated the effects of adding dexamethasone to the care of the regimen in adults receiving invasive ventilation, those receiving oxygen (e.g. through a mask) or those who do not receive oxygen. . In the study, all deaths occurring 28 days after initiation of the remedy with dexamethasone were recorded and the initial effects imply that dexamethasone reduced mortality in patients receiving respiratory assistance compared to the same previous care.
With this review, the EMA hopes to provide an opinion on the RECOVERY test and also on the prospective use of dexamethasone for the treatment of adults with COVID-19. More data will be presented through the company when available.
Source: EMA